News
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
6/28sat.16:30～呼吸器内科 医局説明会を開催します☆
熊本大学 呼吸器内科
